QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
NASDAQ:LQDA

Liquidia (LQDA) Stock Price, News & Analysis

$14.77
-0.30 (-1.99%)
(As of 01:22 PM ET)
Today's Range
$14.76
$15.12
50-Day Range
$11.97
$16.73
52-Week Range
$5.71
$16.99
Volume
444,267 shs
Average Volume
960,863 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Liquidia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
42.2% Upside
$21.00 Price Target
Short Interest
Bearish
9.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Liquidia in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$862,904 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.01) to ($0.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.61 out of 5 stars

Medical Sector

546th out of 939 stocks

Pharmaceutical Preparations Industry

253rd out of 433 stocks

LQDA stock logo

About Liquidia Stock (NASDAQ:LQDA)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

LQDA Stock Price History

LQDA Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Liquidia (NASDAQ:LQDA) Hits New 52-Week High at $16.74
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
LQDA Apr 2024 7.500 call
Liquidia Full Year 2023 Earnings: Misses Expectations
Unveiling 6 Analyst Insights On Liquidia
What Wall Street expects from Liquidia Technologies's earnings
Liquidia Stock (NASDAQ:LQDA), Short Interest Report
See More Headlines
Receive LQDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liquidia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LQDA
Fax
N/A
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$32.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+39.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-78,500,000.00
Net Margins
-448.89%
Pretax Margin
-448.89%

Debt

Sales & Book Value

Annual Sales
$17.49 million
Book Value
$0.73 per share

Miscellaneous

Free Float
52,003,000
Market Cap
$1.15 billion
Optionable
Optionable
Beta
0.14
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Roger A. Jeffs Ph.D. (Age 62)
    CEO & Director
    Comp: $532.23k
  • Mr. Michael Kaseta (Age 47)
    COO & CFO
    Comp: $627.85k
  • Mr. Russell SchundlerMr. Russell Schundler (Age 49)
    General Counsel & Corporate Secretary
    Comp: $541.92k
  • Mr. William R. Kenan Jr.
    Co-Founder
  • Dr. Ginger Denison
    Co-Founder
  • Jennifer Almond
    Director of Investor Relations & Corporate Communications
  • Ms. Sarah Krepp SPHR
    Vice President of People & Culture
  • Mr. Jason Adair (Age 50)
    Chief Business Officer
  • Dr. Tushar Shah M.D. (Age 63)
    Senior Vice President of Product Development
    Comp: $792.36k
  • Mr. Scott Moomaw (Age 53)
    Chief Commercial Officer

LQDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Liquidia stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LQDA shares.
View LQDA analyst ratings
or view top-rated stocks.

What is Liquidia's stock price target for 2024?

5 Wall Street research analysts have issued 12 month price objectives for Liquidia's shares. Their LQDA share price targets range from $3.00 to $32.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for LQDA
or view top-rated stocks among Wall Street analysts.

How have LQDA shares performed in 2024?

Liquidia's stock was trading at $12.03 at the beginning of 2024. Since then, LQDA stock has increased by 22.8% and is now trading at $14.77.
View the best growth stocks for 2024 here
.

When is Liquidia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LQDA earnings forecast
.

How were Liquidia's earnings last quarter?

Liquidia Co. (NASDAQ:LQDA) issued its earnings results on Wednesday, November, 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.02. The firm earned $3.18 million during the quarter, compared to analysts' expectations of $2.48 million. Liquidia had a negative trailing twelve-month return on equity of 132.16% and a negative net margin of 448.89%.

What ETF holds Liquidia's stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 13,817 shares of LQDA stock, representing 0.92% of its portfolio.

What other stocks do shareholders of Liquidia own?
When did Liquidia IPO?

Liquidia (LQDA) raised $50 million in an IPO on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia's major shareholders?

Liquidia's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.38%), Vanguard Group Inc. (4.38%), Kynam Capital Management LP (4.16%), Findell Capital Management LLC (3.21%), Vestal Point Capital LP (1.58%) and Opaleye Management Inc. (0.69%). Insiders that own company stock include Arthur S Kirsch, Caligan Partners Lp, Jason Adair, Michael Kaseta, Paul B Manning, Robert A Lippe, Roger Jeffs, Russell Schundler and Scott Moomaw.
View institutional ownership trends
.

How do I buy shares of Liquidia?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LQDA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners